富瑞:下調百勝中國(9987.HK)目標價11%,維持“買入”評級
格隆匯5月5日丨富瑞發研報指,內地封城措施繼續影響百勝中國(9987.HK)今年第二季的表現,決定下調公司2022-24年純利預測分別72%、37%及19%,目標價亦隨之調低11%至459.16港元,但維持“買入”評級不變。報吿指出,封城影響遍及各行各業,不致損害百勝資產,而管理層擴大零售網絡的長期策略亦未有改變。雖然富瑞以至其他證券行,此前並無預期百勝第二季業見紅,但內地堅持清零政策下,相信大部分投資者對百勝季績已不抱厚望,假設5、6月市況未能改善,管理層預計第二季公司業績將錄得虧損,富瑞估計將蝕約1.17億美元,而第三季表現可望逐步復甦。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.